Drug Coated Balloon Catheter Market is predicted to reach USD 1.7 billion at a CAGR of 12% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Drug Coated Balloon Catheter Market”.

The Drug Coated Balloon Catheter market is estimated to register a CAGR of 12.00% during the forecast period of 2024 to 2032.

MRFR recognizes the following companies as the key players in the global Drug Coated Balloon Catheter market— Bayer AG, B. Braun SE, Eurocor GmbH, Biosensors International Group, Boston Scientific Corporation, iVascular, Medtronic plc, BIOTRONIK, Caliber Therapeutics, Concept Medical Research.

Drug Coated Balloon Catheter Market Highlights

The global Drug Coated Balloon Catheter market is accounted to register a CAGR of 12.00% during the forecast period and is estimated to reach USD 1.7 billion by 2032.

The demographic shift that is propelling the market's expansion is the aging of the population. In addition, a growing population that is more vulnerable to cardiovascular illnesses and rising healthcare costs are propelling market expansion. The market expansion is being impeded by the exorbitant cost of these devices and their essential components. Furthermore, the high expense of catheterization treatments may limit market expansion in developing nations with somewhat low-income levels. This increase in medical equipment modernization and technological advancements.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Drug Coated Balloon Catheter Market Research Report

Segment Analysis

The global Drug Coated Balloon Catheter market has been segmented based on Type, Product and End-use.

On the basis of Type, the market is segmented into Paclitaxel and Sirolimus. The Paclitaxel segment was attributed to holding the largest market share in 2023. This is due to a number of factors that have been connected to the rise in cardiovascular diseases, including lifestyle decisions and environmental effects.

Based on Product, the global Drug Coated Balloon Catheter market has been segmented into Coronary Artery Disease and Peripheral Vascular Disease. The Peripheral Vascular Disease segment was expected to hold the largest market share in 2023. This is because balloon catheters for the peripheral vascular system improve patient safety during surgical procedures.

Based on end-use, the global drug-coated balloon catheter market has been segmented into hospitals, clinics, and ambulatory surgical centers. The Hospital segment was expected to hold the largest market share in 2023. This is due to the fact that an increase in hospital in-patient admissions for catheterization procedures is predicted to fuel market growth.

Regional Analysis

The global Drug Coated Balloon Catheter market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of the US and Canada. The Europe Drug Coated Balloon Catheter market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Drug Coated Balloon Catheter market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Drug Coated Balloon Catheter market comprises of Middle East, Africa, and Latin America.

The largest market share for Drug Coated Balloon Catheter was maintained by the North American regional sector. This increase is due to the market for drug-eluting balloon catheters, which is dominated by North America because of a number of factors, including the region's high concentration of highly skilled surgeons and the rising incidence of urological and renal failure. In addition, a rise in the number of residents having angioplasty procedures and the USFDA's quick approval process for balloon catheters—which are classified as class II medical devices—are contributing to the expansion of this industry.

Moreover, the Europe market has been persistently growing over the forecast period because Europe's medical tourism industry is expanding as a result of continuous infrastructure improvements in the field and the expansion of medical travel throughout numerous emerging nations.

Additionally, throughout the projection period, Asia Pacific is anticipated to grow at the quickest rate due to the rising popularity and accessibility of minimally invasive surgeries. Additionally, the rising incidence of cardiovascular illnesses in developing nations like Brazil and India is supporting the expansion of the market in this area. Furthermore, during the course of the forecast period, the region's medical tourism industry is expected to grow at the fastest rate possible, in tandem with the rapidly expanding healthcare infrastructure.

Furthermore, the rest of the world's Drug Coated Balloon Catheter market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the growing number of people becoming patients due to reasons like aging populations and improved awareness and detection of arrhythmias. Government support, a rise in investor interest, and the viability of the technology in the sector are all contributing factors to the market expansion.

Key Findings of the Study

• The global Drug Coated Balloon Catheter market is expected to reach USD 7 billion by 2032, at a CAGR of 12.00% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the rising incidence of cardiovascular illnesses in developing nations like Brazil and India, which is supporting the expansion of the market in this area.


• Based on the product, the Peripheral Vascular Disease segment was expected to hold the largest market share in 2023.


• Bayer AG, B. Braun SE, Eurocor GmbH, Biosensors International Group, Boston Scientific Corporation, iVascular, Medtronic plc, BIOTRONIK, Caliber Therapeutics, and Concept Medical Research are the key market players.